SupplySide West 2019 preview: Kappa Bioscience to unveil results of global vitamin K2 quality study

October 1, 2019

Kappa Bioscience (Oslo, Norway), maker of K2Vital vitamin K2 MK-7, has announced that it will be unveiling the results of a multi-year global study on vitamin K2 quality at SupplySide West, taking place in Las Vegas, NV. The study’s findings show an increased use of stability-enhanced K2 MK-7 among finished product manufacturers, with three companies currently offering stability-enhanced MK-7. Vitamin K2 is often paired with minerals such as calcium or magnesium, but unprotected vitamin K2 is not stable with minerals, says Kappa Bioscience. That is why Kappa and other manufacturers microencapsulate MK-7 in mineral formulations. However, the study shows too many unprotected vitamin K2 mineral combination products are sold to consumers, and only one in five products meet label claims.

“Explosive vitamin K2 growth has been driven by many factors, including increased consumer awareness and a consistently declining ingredient price. A current daily dose costs less than two cents, allowing K2 to be used in a broader number of product categories,” said Garnet Pigden, president of Kappa Bioscience USA, in a press release. “The new study demonstrates that while K2 is moving onto the mainstream, brand owners should take care to use only quality K2 and investigate options for protected K2 in formulations that require stability solutions.”

“Independent quality testing is a solution that protects the industry and consumers. We know that other premium ingredient manufacturers agree, and that the time is right to implement new standards of quality, transparency, and ethical behavior,” added Jörg Büttinghaus, Kappa’s VP of sales and marketing, in a press release. “At SSW we’d like to hear from any company that has also had to fight for quality in their market.”

Kappa Bioscience can be found at booth 4515.